Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor

Details for Australian Patent Application No. 2011202833 (hide)

Owner Novartis AG

Inventors Manley, Paul W.

Agent Davies Collison Cave

Pub. Number AU-B-2011202833

Parent 2007235900

Filing date 14 June 2011

Wipo publication date 7 July 2011

Acceptance publication date 24 May 2012

International Classifications

A61K 31/497 (2006.01)

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 17/06 (2006.01) Drugs for dermatological disorders

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/02 (2006.01) Antineoplastic agents

Event Publications

30 June 2011 Complete Application Filed

7 July 2011 Application Open to Public Inspection

  Published as AU-B-2011202833

24 May 2012 Application Accepted

  Published as AU-B-2011202833

20 September 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011202834-Line filter of a hydraulic installation

2011202832-Mobile terminal and method of controlling a mode switching therein